secwatch.observer — SEC 8-K summary
======================================

Issuer:     Vera Therapeutics, Inc. (VERA)
CIK:        0001831828
Form:       8-K
Filed at:   2025-11-06T23:59:59+00:00
Accession:  0001193125-25-268331
Event type: other_material
Sentiment:  positive
Materiality: 0.95
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Vera Therapeutics announces atacicept Phase 3 data: 46% proteinuria reduction, 42% vs placebo (p<0.0001)
--------------------------------------------------------------------------------

- Atacicept achieved 46% reduction from baseline in UPCR at week 36; 42% reduction vs placebo (p<0.0001).
- Secondary endpoints: Gd-IgA1 reduced by 68%; hematuria resolved in 81% of participants with baseline hematuria.
- Safety profile favorable: serious adverse events 0.5% (atacicept) vs 5% (placebo); no deaths in either group.
- eGFR results not disclosed per FDA recommendation to sponsors of IgAN registrational trials.
- Data presented at ASN Kidney Week and simultaneously published in The New England Journal of Medicine.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1831828/000119312525268331/0001193125-25-268331-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1831828/000119312525268331/d30094d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-25-268331

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer